levothyroxine sodium
- Product NDC
- 47781-643
- 11-digit product format
- 477810643
- Labeler code
- 47781
- Product ID
- 47781-643_3b8c38aa-ac99-1c0d-42f3-4fe8881125dc
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- levothyroxine sodium
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Alvogen, Inc.
- Application
- NDA021116
- Marketing category
- NDA
- Marketing start
- 2019-05-07
- Substance
- LEVOTHYROXINE SODIUM
- Active strength
- 50 ug/1
- Pharmacologic classes
- Thyroxine [CS], l-Thyroxine [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021116-001 | THYRO-TABS | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 |
| N021116-002 | THYRO-TABS | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 |
| N021116-003 | THYRO-TABS | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 |
| N021116-004 | THYRO-TABS | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 |
| N021116-005 | THYRO-TABS | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 |
| N021116-006 | THYRO-TABS | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 |
| N021116-007 | THYRO-TABS | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 |
| N021116-008 | THYRO-TABS | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 |
| N021116-009 | THYRO-TABS | LEVOTHYROXINE SODIUM | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 |
| N021116-010 | THYRO-TABS | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 |
| N021116-011 | THYRO-TABS | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 |
| N021116-012 | THYRO-TABS | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2004-12-07 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| N021116-001 | AB1 |
| N021116-001 | AB2 |
| N021116-001 | AB3 |
| N021116-001 | AB4 |
| N021116-002 | AB1 |
| N021116-002 | AB2 |
| N021116-002 | AB3 |
| N021116-002 | AB4 |
| N021116-003 | AB1 |
| N021116-003 | AB2 |
| N021116-003 | AB3 |
| N021116-003 | AB4 |
| N021116-004 | AB1 |
| N021116-004 | AB2 |
| N021116-004 | AB3 |
| N021116-004 | AB4 |
| N021116-005 | AB1 |
| N021116-005 | AB2 |
| N021116-005 | AB3 |
| N021116-005 | AB4 |
| N021116-006 | AB1 |
| N021116-006 | AB2 |
| N021116-006 | AB3 |
| N021116-006 | AB4 |
| N021116-007 | AB1 |
| N021116-007 | AB2 |
| N021116-007 | AB3 |
| N021116-007 | AB4 |
| N021116-008 | AB1 |
| N021116-008 | AB2 |
| N021116-008 | AB3 |
| N021116-008 | AB4 |
| N021116-009 | AB1 |
| N021116-009 | AB2 |
| N021116-009 | AB3 |
| N021116-009 | AB4 |
| N021116-010 | AB1 |
| N021116-010 | AB2 |
| N021116-010 | AB3 |
| N021116-010 | AB4 |
| N021116-011 | AB1 |
| N021116-011 | AB2 |
| N021116-011 | AB3 |
| N021116-011 | AB4 |
| N021116-012 | AB1 |
| N021116-012 | AB2 |
| N021116-012 | AB3 |
| N021116-012 | AB4 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021116-001 | THYRO-TABS | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-002 | THYRO-TABS | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-003 | THYRO-TABS | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-004 | THYRO-TABS | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-005 | THYRO-TABS | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-006 | THYRO-TABS | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-007 | THYRO-TABS | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-008 | THYRO-TABS | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-009 | THYRO-TABS | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-010 | THYRO-TABS | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-011 | THYRO-TABS | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-012 | THYRO-TABS | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2004-12-07 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N021116-001 | THYRO-TABS | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021116-002 | THYRO-TABS | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021116-003 | THYRO-TABS | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021116-004 | THYRO-TABS | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021116-005 | THYRO-TABS | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021116-006 | THYRO-TABS | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021116-007 | THYRO-TABS | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021116-008 | THYRO-TABS | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021116-009 | THYRO-TABS | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021116-010 | THYRO-TABS | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021116-011 | THYRO-TABS | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021116-012 | THYRO-TABS | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2004-12-07 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N021116-001 | THYRO-TABS | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021116-002 | THYRO-TABS | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021116-003 | THYRO-TABS | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021116-004 | THYRO-TABS | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021116-005 | THYRO-TABS | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021116-006 | THYRO-TABS | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021116-007 | THYRO-TABS | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021116-008 | THYRO-TABS | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021116-009 | THYRO-TABS | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021116-010 | THYRO-TABS | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021116-011 | THYRO-TABS | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021116-012 | THYRO-TABS | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2004-12-07 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021116-001 | THYRO-TABS | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021116-002 | THYRO-TABS | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021116-003 | THYRO-TABS | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021116-004 | THYRO-TABS | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | AB1,AB2,AB3,AB4 | RLD | 2002-10-24 | 31067a03dcf5… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021116-001 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-001 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-001 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-001 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-002 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-002 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-002 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-002 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-003 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-003 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-003 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-003 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-004 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-004 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-004 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-004 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-005 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-005 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-005 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-005 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-006 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-006 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-006 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-006 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-007 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-007 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-007 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-007 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-008 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-008 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-008 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-008 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-009 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-009 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-009 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-009 | AB4 | 4 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-010 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-010 | AB2 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-010 | AB3 | 3 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021116-010 | AB4 | 4 | 84e616aacf4f… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- levothyroxine sodium
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| LEVOTHYROXINE SODIUM | 50 ug/1 |
DailyMed Product Concepts#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 47781-643-10 | levothyroxine sodium | 1000 in 1 BOTTLE | TABLET | 1000 | 7 | |
| 47781-643-90 | levothyroxine sodium | 90 in 1 BOTTLE | TABLET | 90 | 7 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 47781-643-10 | EA - Each | 47781-643 | 5a0f4aaf-2723-449b-bf5f-92d1bca6b73b | 1 | 2019-06-19 |
| 47781-643-90 | EA - Each | 47781-643 | 500796fd-6b3d-4c58-ab73-97148a0686f2 | 1 | 2019-06-19 |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | fc803107-aaa2-4753-ab97-7b4ed5cf4be5 | 2025-01-21 | Boxed warning, Warnings, Adverse reactions | 021116 NDA021116 |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | d79526e0-d327-4545-a50c-99678766d817 | 2024-08-06 | Boxed warning, Warnings, Adverse reactions | 021116 NDA021116 |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | c22af2e0-fb36-4645-a911-3d293af5bd88 | 2024-08-06 | Boxed warning, Warnings, Adverse reactions | 021116 NDA021116 |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals,Inc. | a2157cf0-5c8f-7e69-e053-2a95a90aa083 | 2024-06-20 | Boxed warning, Warnings, Adverse reactions | 021116 NDA021116 |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals,Inc. | a215da96-acd9-6b8d-e053-2995a90a7e0d | 2024-06-20 | Boxed warning, Warnings, Adverse reactions | 021116 NDA021116 |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | NuCar Pharmaceuticals,Inc. | a2194c58-b755-e6b5-e053-2a95a90a36d4 | 2024-06-20 | Boxed warning, Warnings, Adverse reactions | 021116 NDA021116 |
| LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | DIRECT RX | a5f15022-1166-09fe-e053-2a95a90aa218 | 2024-05-23 | Boxed warning, Warnings, Adverse reactions | 021116 NDA021116 |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | 8849620a-5e8d-4031-884f-9a2817b050f2 | 2024-05-02 | Boxed warning, Warnings, Adverse reactions | 021116 NDA021116 |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | d35b5250-c26d-4d67-8a33-2f993b13e3e9 | 2024-04-08 | Boxed warning, Warnings, Adverse reactions | 021116 NDA021116 |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Proficient Rx LP | 2daab9ce-0570-4fdf-a7bd-01c3178f8cf3 | 2021-03-01 | Boxed warning, Warnings, Adverse reactions | 021116 NDA021116 |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Proficient Rx LP | 12ccf2fd-ccf0-4bcf-8eee-e2a16c8b44d6 | 2020-12-01 | Boxed warning, Warnings, Adverse reactions | 021116 NDA021116 |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Proficient Rx LP | 3019762c-d480-4530-a3b2-762b523e7961 | 2019-11-01 | Boxed warning, Warnings, Adverse reactions | 021116 NDA021116 |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 966221 | levothyroxine sodium 50 MCG Oral Tablet | PSN | c22af2e0-fb36-4645-a911-3d293af5bd88 | 105 |
| 966221 | levothyroxine sodium 0.05 MG Oral Tablet | SCD | c22af2e0-fb36-4645-a911-3d293af5bd88 | 105 |
| 966221 | levothyroxine sodium 50 MCG Oral Tablet | SY | c22af2e0-fb36-4645-a911-3d293af5bd88 | 105 |
| 966221 | levothyroxine sodium 50 MCG Oral Tablet | PSN | c1b0fbad-5816-4152-ab59-05079e8c2148 | 102 |
| 966221 | levothyroxine sodium 0.05 MG Oral Tablet | SCD | c1b0fbad-5816-4152-ab59-05079e8c2148 | 102 |
| 966221 | levothyroxine sodium 50 MCG Oral Tablet | SY | c1b0fbad-5816-4152-ab59-05079e8c2148 | 102 |
| 892246 | levothyroxine sodium 100 MCG Oral Tablet | PSN | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966248 | levothyroxine sodium 112 MCG Oral Tablet | PSN | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966224 | levothyroxine sodium 125 MCG Oral Tablet | PSN | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966270 | levothyroxine sodium 137 MCG Oral Tablet | PSN | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966225 | levothyroxine sodium 150 MCG Oral Tablet | PSN | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966249 | levothyroxine sodium 175 MCG Oral Tablet | PSN | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 892251 | levothyroxine sodium 200 MCG Oral Tablet | PSN | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966220 | levothyroxine sodium 25 MCG Oral Tablet | PSN | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966221 | levothyroxine sodium 50 MCG Oral Tablet | PSN | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966222 | levothyroxine sodium 75 MCG Oral Tablet | PSN | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966253 | levothyroxine sodium 88 MCG Oral Tablet | PSN | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966220 | levothyroxine sodium 0.025 MG Oral Tablet | SCD | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966221 | levothyroxine sodium 0.05 MG Oral Tablet | SCD | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966222 | levothyroxine sodium 0.075 MG Oral Tablet | SCD | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966253 | levothyroxine sodium 0.088 MG Oral Tablet | SCD | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 892246 | levothyroxine sodium 0.1 MG Oral Tablet | SCD | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966248 | levothyroxine sodium 0.112 MG Oral Tablet | SCD | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966224 | levothyroxine sodium 0.125 MG Oral Tablet | SCD | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966270 | levothyroxine sodium 0.137 MG Oral Tablet | SCD | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966225 | levothyroxine sodium 0.15 MG Oral Tablet | SCD | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966249 | levothyroxine sodium 0.175 MG Oral Tablet | SCD | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 892251 | levothyroxine sodium 0.2 MG Oral Tablet | SCD | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 892246 | levothyroxine sodium 100 MCG Oral Tablet | SY | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966248 | levothyroxine sodium 112 MCG Oral Tablet | SY | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966224 | levothyroxine sodium 125 MCG Oral Tablet | SY | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966270 | levothyroxine sodium 137 MCG Oral Tablet | SY | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966225 | levothyroxine sodium 150 MCG Oral Tablet | SY | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966249 | levothyroxine sodium 175 MCG Oral Tablet | SY | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 892251 | levothyroxine sodium 200 MCG Oral Tablet | SY | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966220 | levothyroxine sodium 25 MCG Oral Tablet | SY | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966221 | levothyroxine sodium 50 MCG Oral Tablet | SY | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966222 | levothyroxine sodium 75 MCG Oral Tablet | SY | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 966253 | levothyroxine sodium 88 MCG Oral Tablet | SY | 9e3bffb9-f66e-4c73-befc-e60d769f6610 | 26 |
| 892246 | levothyroxine sodium 100 MCG Oral Tablet | PSN | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966248 | levothyroxine sodium 112 MCG Oral Tablet | PSN | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966224 | levothyroxine sodium 125 MCG Oral Tablet | PSN | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966270 | levothyroxine sodium 137 MCG Oral Tablet | PSN | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966225 | levothyroxine sodium 150 MCG Oral Tablet | PSN | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966220 | levothyroxine sodium 25 MCG Oral Tablet | PSN | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966221 | levothyroxine sodium 50 MCG Oral Tablet | PSN | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966222 | levothyroxine sodium 75 MCG Oral Tablet | PSN | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966253 | levothyroxine sodium 88 MCG Oral Tablet | PSN | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966220 | levothyroxine sodium 0.025 MG Oral Tablet | SCD | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966221 | levothyroxine sodium 0.05 MG Oral Tablet | SCD | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966222 | levothyroxine sodium 0.075 MG Oral Tablet | SCD | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966253 | levothyroxine sodium 0.088 MG Oral Tablet | SCD | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 892246 | levothyroxine sodium 0.1 MG Oral Tablet | SCD | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966248 | levothyroxine sodium 0.112 MG Oral Tablet | SCD | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966224 | levothyroxine sodium 0.125 MG Oral Tablet | SCD | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966270 | levothyroxine sodium 0.137 MG Oral Tablet | SCD | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966225 | levothyroxine sodium 0.15 MG Oral Tablet | SCD | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 892246 | levothyroxine sodium 100 MCG Oral Tablet | SY | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966248 | levothyroxine sodium 112 MCG Oral Tablet | SY | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966224 | levothyroxine sodium 125 MCG Oral Tablet | SY | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966270 | levothyroxine sodium 137 MCG Oral Tablet | SY | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966225 | levothyroxine sodium 150 MCG Oral Tablet | SY | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966220 | levothyroxine sodium 25 MCG Oral Tablet | SY | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966221 | levothyroxine sodium 50 MCG Oral Tablet | SY | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966222 | levothyroxine sodium 75 MCG Oral Tablet | SY | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 966253 | levothyroxine sodium 88 MCG Oral Tablet | SY | a5f15022-1166-09fe-e053-2a95a90aa218 | 21 |
| 892246 | levothyroxine sodium 100 MCG Oral Tablet | PSN | 4ddcaec1-a58f-340b-9bc1-bbe048b8c885 | 7 |
| 966248 | levothyroxine sodium 112 MCG Oral Tablet | PSN | 4ddcaec1-a58f-340b-9bc1-bbe048b8c885 | 7 |
| 966224 | levothyroxine sodium 125 MCG Oral Tablet | PSN | 4ddcaec1-a58f-340b-9bc1-bbe048b8c885 | 7 |
| 966270 | levothyroxine sodium 137 MCG Oral Tablet | PSN | 4ddcaec1-a58f-340b-9bc1-bbe048b8c885 | 7 |
| 966225 | levothyroxine sodium 150 MCG Oral Tablet | PSN | 4ddcaec1-a58f-340b-9bc1-bbe048b8c885 | 7 |
| 966249 | levothyroxine sodium 175 MCG Oral Tablet | PSN | 4ddcaec1-a58f-340b-9bc1-bbe048b8c885 | 7 |
| 892251 | levothyroxine sodium 200 MCG Oral Tablet | PSN | 4ddcaec1-a58f-340b-9bc1-bbe048b8c885 | 7 |
| 966220 | levothyroxine sodium 25 MCG Oral Tablet | PSN | 4ddcaec1-a58f-340b-9bc1-bbe048b8c885 | 7 |
| 892255 | levothyroxine sodium 300 MCG Oral Tablet | PSN | 4ddcaec1-a58f-340b-9bc1-bbe048b8c885 | 7 |
| 966221 | levothyroxine sodium 50 MCG Oral Tablet | PSN | 4ddcaec1-a58f-340b-9bc1-bbe048b8c885 | 7 |
| 966222 | levothyroxine sodium 75 MCG Oral Tablet | PSN | 4ddcaec1-a58f-340b-9bc1-bbe048b8c885 | 7 |
| 966253 | levothyroxine sodium 88 MCG Oral Tablet | PSN | 4ddcaec1-a58f-340b-9bc1-bbe048b8c885 | 7 |
| 966220 | levothyroxine sodium 0.025 MG Oral Tablet | SCD | 4ddcaec1-a58f-340b-9bc1-bbe048b8c885 | 7 |
| 966221 | levothyroxine sodium 0.05 MG Oral Tablet | SCD | 4ddcaec1-a58f-340b-9bc1-bbe048b8c885 | 7 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|---|
| 47781-643-10 | 47781064310 | 1000 TABLET in 1 BOTTLE (47781-643-10) | 1000 tablet | 2019-05-07 | 0000-00-00 | No | No | Current |
| 47781-643-90 | 47781064390 | 90 TABLET in 1 BOTTLE (47781-643-90) | 90 tablet | 2019-05-07 | 0000-00-00 | No | No | Current |